Open Access

Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

  • Erwann P. Loret1Email author,
  • Albert Darque1, 3,
  • Elisabeth Jouve4,
  • Elvenn A. Loret1,
  • Corinne Nicolino-Brunet1,
  • Sophie Morange2,
  • Elisabeth Castanier2,
  • Josiane Casanova2,
  • Christine Caloustian2,
  • Charléric Bornet3,
  • Julie Coussirou3,
  • Jihen Boussetta3,
  • Vincent Couallier5,
  • Olivier Blin4,
  • Bertrand Dussol2 and
  • Isabelle Ravaux1
Retrovirology201613:35

https://doi.org/10.1186/s12977-016-0264-y

Published: 9 May 2016

The original article was published in Retrovirology 2016 13:21

Erratum to: Retrovirology (2016) 13:21 DOI 10.1186/s12977-016-0251-3

The original version of this article unfortunately contained a mistake. The “Acknowledgement” section was incorrect and included Dr. Catherine Tamalet. Dr. Catherine Tamalet should not be included in the “Acknowledgement” section for the following reasons:

Dr. Catherine Tamalet requests to be withdrawn from the “Acknowledgements” section in this article, on the following grounds: (a) No permission was asked of her to be acknowledged. (b) She did not read the manuscript before its publication. (c) The method depicted in the “Methods” section to quantify HIV DNA [“Generic HIV assay (Biocentric, Bandol, Provence) with a cut off of 20 copies/million of peripheral blood mononuclear cells (PBMC)”] is not the method employed in her laboratory. Dr. Tamaret routinely employs an “in-House” method with a cut-off of 20 copies. Dr. Thamalet was in the acknowledgement for fruitful discussion and not for her participation to the study.

Dr. Catherine Tamalet has been removed from the original article [1].

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
ETRAV Laboratory, Faculty of Pharmacy, Centre National de la Recherche Scientifique (CNRS), Aix Marseille University
(2)
Centre d’Investigation Clinique, Assistance Publique –Hôpitaux de Marseille (AP-HM), University Hospital Center (UHC) «la Conception»
(3)
Pharmacie Usage Interne, AP-HM, UHC «la Conception»
(4)
Centre de Pharmacologie Clinique et Evaluations Thérapeutiques (AP-HM), UHC «la Timone»
(5)
Unité Mixte de Recherche CNRS 5251, Institut de Mathématique de Bordeaux, CNRS, Bordeaux 2 University

Reference

  1. Loret EP, et al. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology. 2016;13:21. doi:10.1186/s12977-016-0251-3.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Loret et al. 2016

Advertisement